Related Experiment Video

Updated: May 1, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

The cost-effectiveness of boceprevir for hepatitis C

Chin Fen Neoh1, David C M Kong

  • 1University of Technology Mara - Collaborative Drug Discovery Research (CDDR) Group, Faculty of Pharmacy, Selangor, Malaysia.

Expert Review of Pharmacoeconomics & Outcomes Research
|April 9, 2014
PubMed

Insights

New Hepatitis C virus (HCV) protease inhibitors offer better efficacy but increase costs. This review examines the clinical and economic factors of boceprevir-based treatments to guide healthcare decisions.

Area of Science:

  • Hepatology
  • Pharmacoeconomics
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection presents significant morbidity, mortality, and treatment costs.
  • Standard therapy involves pegylated interferon-alfa and ribavirin.
  • Emerging protease inhibitors like boceprevir and telaprevir offer improved efficacy and shorter treatment durations.

Purpose of the Study:

  • To review the clinical and economic aspects of boceprevir-based treatment strategies for HCV.
  • To highlight considerations, challenges, and gaps in pharmacoeconomic research for these antiviral agents.

Main Methods:

  • Literature review of clinical trial data.
  • Economic evaluation of HCV treatment regimens.
  • Analysis of adverse events and drug acquisition costs.

Main Results:

  • Boceprevir-based therapies demonstrate superior efficacy and shorter treatment durations compared to standard therapy.
  • These newer agents are associated with higher drug acquisition costs and an increased incidence of adverse events.
  • Economic data are crucial for informed healthcare decisions regarding the optimal use of expensive antiviral agents.

Conclusions:

  • Boceprevir-based treatment strategies offer clinical benefits but require careful economic evaluation.
  • Further pharmacoeconomic research is needed to address the challenges and gaps in optimizing the use of novel HCV therapies.

Keywords:
costseconomichepatitis C infectionmodelingprotease inhibitors

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

6.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.9K

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
725